<p>Dyne Therapeutics（納斯達克代碼：DYN - 獲取免費報告）於週一發佈了其財報。該公司報告本季度每股收益為（$0.73），超出分析師一致預期的（$0.74）$0.01，RTT News 報道。在去年同期，該公司每股收益為（$1.05）。</p>
<p>獲取 <strong>Dyne Therapeutics</strong> 的提醒：</p>
<h2>Dyne Therapeutics 股票表現</h2>
<p>週一交易時段，Dyne Therapeutics 股票上漲 $0.61，達到 $18.22。該股票成交量為 336,444 股，而其平均成交量為 2,062,577 股。該公司的債務與股本比率為 0.15，流動比率為 22.25，速動比率為 22.25。該公司的 50 日移動平均價格為$18.05，200 日移動平均價格為$18.59。該股票的市值為 30.1 億美元，市盈率為-5.15，貝塔值為 1.08。Dyne Therapeutics 的 1 年最低價為$8.06，1 年最高價為$25.00。</p>
<h2>分析師評級變動</h2>
<p>DYN 曾受到多家研究分析師的關注。Chardan Capital 在 3 月 9 日的研究報告中重申了對 Dyne Therapeutics 的 “買入” 評級，並設定了$38.00 的目標價。Wall Street Zen 在 5 月 2 日的研究報告中將 Dyne Therapeutics 的評級從 “賣出” 下調至 “強烈賣出”。HC Wainwright 在 3 月 3 日的研究報告中將 Dyne Therapeutics 的目標價從$60.00 下調至$50.00，並給予該公司 “買入” 評級。摩根士丹利在 3 月 2 日的研究報告中將 Dyne Therapeutics 的目標價從$50.00 下調至$47.00，並給予該公司 “增持” 評級。最後，摩根大通在 1 月 20 日的研究報告中將 Dyne Therapeutics 的目標價從$17.00 下調至$16.00，並給予該公司 “中性” 評級。三位投資分析師對該股票給予了 “強烈買入” 評級，十一位給予了 “買入” 評級，兩位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，共識目標價為$35.14。</p>
<p><strong>獲取我們對 Dyne Therapeutics 的最新股票分析</strong></p>
<h2>內部人士下注</h2>
<p>在其他 Dyne Therapeutics 的新聞中，董事 Jason P. Rhodes 於 5 月 6 日出售了 83,219 股該公司的股票。該股票以平均價格$18.18 出售，總交易額為$1,512,921.42。出售後，該董事在公司持有 7,962 股，價值約$144,749.16。此次交易使其持股減少了 91.27%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過 SEC 網站訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。在上個季度，內部人士出售了價值$29,694,469 的 1,552,911 股公司股票。目前，內部人士持有該公司 20.77% 的股票。</p>
<h2>Dyne Therapeutics 的機構交易</h2>
<p>多家對沖基金最近調整了對 DYN 的持股。T. Rowe Price Investment Management Inc.在第四季度將其在 Dyne Therapeutics 的持股增加了 523.7%。T. Rowe Price Investment Management Inc.現在擁有 17,540,089 股該公司的股票，價值$343,085,000，在此期間又購買了 14,727,667 股。Orbis Allan Gray Ltd 在第四季度獲得了 Dyne Therapeutics 的新頭寸，價值約$93,926,000。Adage Capital Partners GP L.L.C.在第二季度獲得了 Dyne Therapeutics 的新頭寸，價值約$30,378,000。Marshall Wace LLP 在第三季度將其在 Dyne Therapeutics 的持股增加了 572.9%。Marshall Wace LLP 現在擁有 3,013,377 股該公司的股票，價值$38,119,000，在此期間又購買了 2,565,570 股。最後，Vestal Point Capital LP 在第三季度將其在 Dyne Therapeutics 的持股增加了 281.4%。Vestal Point Capital LP 現在擁有 2,775,000 股該公司的股票，價值$35,104,000，在此期間又購買了 2,047,500 股。對沖基金和其他機構投資者持有該公司 96.68% 的股票。</p>
<h2>關於 Dyne Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Dyne Therapeutics 是一家臨牀階段的生物技術公司，專注於開發針對嚴重罕見疾病的局部基因調控療法。該公司的專有 FORCE（促進的正交受體介導的貨物評估）平台旨在實現寡核苷酸和基因療法模式的靶向遞送，主要針對骨骼和呼吸肌肉。Dyne 的主要項目集中在杜氏肌營養不良症（DMD）、肌強直性營養不良症 1 型（DM1）和麪肩肱肌營養不良症（FSHD），目前正在進行安全性、耐受性和組織特異性的臨牀前和早期臨牀研究。</p>
<p>自 2019 年由 Flagship Pioneering 創立以來，Dyne 已經通過其模塊化遞送方法推進了多個產品候選者，該方法將工程化配體與治療性載荷結合，以改善肌肉細胞的攝取。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Dyne Therapeutics</li>
<li>AI 股息增加：3 只巨頭提升分紅</li>
<li>瘋狂的週一：這家 SaaS 領軍者的反彈只是個開始</li>
<li>5 只有望受益於 AI 推理熱潮的股票</li>
<li>Meta Platforms 的財報後劇烈波動：分析師的目標價現狀</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Dyne Therapeutics 嗎？</h2>
<p>在考慮 Dyne Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Dyne Therapeutics 並不在名單上。</p>
<p>雖然 Dyne Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

基因改革 ETF - ARK

醫療業 ETF - Vanguard

納斯達克生物科技指數 ETF - iShares Nasdaq

醫療業 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

生物科技 ETF - VanEck Vectors

標普生物技術 ETF - SPDR

<p>Dyne Therapeutics（納斯達克代碼：DYN）公佈了季度財報，報告每股收益（EPS）為（$0.73），超過了預期的（$0.74）。與去年同期的每股收益（$1.05）相比有所改善。股價上漲至$18.22，市值為$30.1 億。分析師的評級意見不一，普遍評級為 “適度買入”，目標價為$35.14。內部人士最近出售了大量股份，機構投資者持有 96.68% 的股份。Dyne 專注於針對罕見疾病的基因調控療法，包括杜氏肌營養不良症</p>

<p>Dyne Therapeutics (NASDAQ:DYN - Get Free Report) issued its earnings results on Monday. The company reported ($0.73) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.01, RTT News reports. During the same period in the prior year, the business earned ($1.05) EPS.</p>
<div class="lb-trans"><p>Dyne Therapeutics（納斯達克代碼：DYN - 獲取免費報告）於週一發佈了其財報。該公司報告本季度每股收益為（$0.73），超出分析師一致預期的（$0.74）$0.01，RTT News 報道。在去年同期，該公司每股收益為（$1.05）。</p>
</div><p>Get <strong>Dyne Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Dyne Therapeutics</strong> 的提醒：</p>
</div><h2>Dyne Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Dyne Therapeutics 股票表現</h2>
</div><p>Dyne Therapeutics stock traded up $0.61 during trading hours on Monday, hitting $18.22. 336,444 shares of the stock traded hands, compared to its average volume of 2,062,577. The company has a debt-to-equity ratio of 0.15, a current ratio of 22.25 and a quick ratio of 22.25. The firm's 50 day moving average price is $18.05 and its 200-day moving average price is $18.59. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of -5.15 and a beta of 1.08. Dyne Therapeutics has a 1 year low of $8.06 and a 1 year high of $25.00.</p>
<div class="lb-trans"><p>週一交易時段，Dyne Therapeutics 股票上漲 $0.61，達到 $18.22。該股票成交量為 336,444 股，而其平均成交量為 2,062,577 股。該公司的債務與股本比率為 0.15，流動比率為 22.25，速動比率為 22.25。該公司的 50 日移動平均價格為$18.05，200 日移動平均價格為$18.59。該股票的市值為 30.1 億美元，市盈率為-5.15，貝塔值為 1.08。Dyne Therapeutics 的 1 年最低價為$8.06，1 年最高價為$25.00。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>DYN has been the subject of a number of research analyst reports. Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. Wall Street Zen lowered Dyne Therapeutics from a &#34;sell&#34; rating to a &#34;strong sell&#34; rating in a research report on Saturday, May 2nd. HC Wainwright decreased their target price on Dyne Therapeutics from $60.00 to $50.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, March 3rd. Morgan Stanley decreased their target price on Dyne Therapeutics from $50.00 to $47.00 and set an &#34;overweight&#34; rating for the company in a research report on Monday, March 2nd. Finally, JPMorgan Chase &amp; Co. decreased their target price on Dyne Therapeutics from $17.00 to $16.00 and set a &#34;neutral&#34; rating for the company in a research report on Tuesday, January 20th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $35.14.</p>
<div class="lb-trans"><p>DYN 曾受到多家研究分析師的關注。Chardan Capital 在 3 月 9 日的研究報告中重申了對 Dyne Therapeutics 的 “買入” 評級，並設定了$38.00 的目標價。Wall Street Zen 在 5 月 2 日的研究報告中將 Dyne Therapeutics 的評級從 “賣出” 下調至 “強烈賣出”。HC Wainwright 在 3 月 3 日的研究報告中將 Dyne Therapeutics 的目標價從$60.00 下調至$50.00，並給予該公司 “買入” 評級。摩根士丹利在 3 月 2 日的研究報告中將 Dyne Therapeutics 的目標價從$50.00 下調至$47.00，並給予該公司 “增持” 評級。最後，摩根大通在 1 月 20 日的研究報告中將 Dyne Therapeutics 的目標價從$17.00 下調至$16.00，並給予該公司 “中性” 評級。三位投資分析師對該股票給予了 “強烈買入” 評級，十一位給予了 “買入” 評級，兩位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，共識目標價為$35.14。</p>
</div><p><strong>Get Our Latest Stock Analysis on Dyne Therapeutics</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Dyne Therapeutics 的最新股票分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other Dyne Therapeutics news, Director Jason P. Rhodes sold 83,219 shares of the business's stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $18.18, for a total transaction of $1,512,921.42. Following the sale, the director owned 7,962 shares in the company, valued at approximately $144,749.16. The trade was a 91.27% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 1,552,911 shares of company stock worth $29,694,469. 20.77% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他 Dyne Therapeutics 的新聞中，董事 Jason P. Rhodes 於 5 月 6 日出售了 83,219 股該公司的股票。該股票以平均價格$18.18 出售，總交易額為$1,512,921.42。出售後，該董事在公司持有 7,962 股，價值約$144,749.16。此次交易使其持股減少了 91.27%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過 SEC 網站訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。在上個季度，內部人士出售了價值$29,694,469 的 1,552,911 股公司股票。目前，內部人士持有該公司 20.77% 的股票。</p>
</div><h2>Institutional Trading of Dyne Therapeutics</h2>
<div class="lb-trans"><h2>Dyne Therapeutics 的機構交易</h2>
</div><p>A number of hedge funds have recently modified their holdings of DYN. T. Rowe Price Investment Management Inc. raised its holdings in Dyne Therapeutics by 523.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company's stock worth $343,085,000 after purchasing an additional 14,727,667 shares during the period. Orbis Allan Gray Ltd acquired a new position in Dyne Therapeutics in the 4th quarter worth about $93,926,000. Adage Capital Partners GP L.L.C. acquired a new position in Dyne Therapeutics in the 2nd quarter worth about $30,378,000. Marshall Wace LLP raised its holdings in Dyne Therapeutics by 572.9% in the 3rd quarter. Marshall Wace LLP now owns 3,013,377 shares of the company's stock worth $38,119,000 after purchasing an additional 2,565,570 shares during the period. Finally, Vestal Point Capital LP raised its holdings in Dyne Therapeutics by 281.4% in the 3rd quarter. Vestal Point Capital LP now owns 2,775,000 shares of the company's stock worth $35,104,000 after purchasing an additional 2,047,500 shares during the period. Hedge funds and other institutional investors own 96.68% of the company's stock.</p>
<div class="lb-trans"><p>多家對沖基金最近調整了對 DYN 的持股。T. Rowe Price Investment Management Inc.在第四季度將其在 Dyne Therapeutics 的持股增加了 523.7%。T. Rowe Price Investment Management Inc.現在擁有 17,540,089 股該公司的股票，價值$343,085,000，在此期間又購買了 14,727,667 股。Orbis Allan Gray Ltd 在第四季度獲得了 Dyne Therapeutics 的新頭寸，價值約$93,926,000。Adage Capital Partners GP L.L.C.在第二季度獲得了 Dyne Therapeutics 的新頭寸，價值約$30,378,000。Marshall Wace LLP 在第三季度將其在 Dyne Therapeutics 的持股增加了 572.9%。Marshall Wace LLP 現在擁有 3,013,377 股該公司的股票，價值$38,119,000，在此期間又購買了 2,565,570 股。最後，Vestal Point Capital LP 在第三季度將其在 Dyne Therapeutics 的持股增加了 281.4%。Vestal Point Capital LP 現在擁有 2,775,000 股該公司的股票，價值$35,104,000，在此期間又購買了 2,047,500 股。對沖基金和其他機構投資者持有該公司 96.68% 的股票。</p>
</div><h2>About Dyne Therapeutics</h2>
<div class="lb-trans"><h2>關於 Dyne Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.</p>
<div class="lb-trans"><p>Dyne Therapeutics 是一家臨牀階段的生物技術公司，專注於開發針對嚴重罕見疾病的局部基因調控療法。該公司的專有 FORCE（促進的正交受體介導的貨物評估）平台旨在實現寡核苷酸和基因療法模式的靶向遞送，主要針對骨骼和呼吸肌肉。Dyne 的主要項目集中在杜氏肌營養不良症（DMD）、肌強直性營養不良症 1 型（DM1）和麪肩肱肌營養不良症（FSHD），目前正在進行安全性、耐受性和組織特異性的臨牀前和早期臨牀研究。</p>
</div><p>Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.</p>
<div class="lb-trans"><p>自 2019 年由 Flagship Pioneering 創立以來，Dyne 已經通過其模塊化遞送方法推進了多個產品候選者，該方法將工程化配體與治療性載荷結合，以改善肌肉細胞的攝取。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than Dyne Therapeutics</li>
<li>AI Dividend Increases: 3 Massive Winners Boosting Payouts</li>
<li>Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader</li>
<li>5 Stocks Positioned to Benefit From the AI Inference Boom</li>
<li>Meta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Dyne Therapeutics</li>
<li>AI 股息增加：3 只巨頭提升分紅</li>
<li>瘋狂的週一：這家 SaaS 領軍者的反彈只是個開始</li>
<li>5 只有望受益於 AI 推理熱潮的股票</li>
<li>Meta Platforms 的財報後劇烈波動：分析師的目標價現狀</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=DYN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Dyne Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Dyne Therapeutics 嗎？</h2>
</div><p>Before you consider Dyne Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Dyne Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Dyne Therapeutics 並不在名單上。</p>
</div><p>While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Dyne Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Dyne Therapeutics (NASDAQ:DYN) Announces Earnings Results

Market Beat

Dyne Therapeutics

摩根士丹利

摩根大通

普信金融

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Dyne Therapeutics (NASDAQ:DYN) 公佈了財務業績